Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 2025 ASCO Annual Meeting took place in Chicago, IL, and online. This meeting attracted thousands of researchers and clinicians who shared the latest advances in the oncology field.

ASCO 2025

29 May–02 June 2025 | Chicago, IL & Online

ASCO 2025

29 May–02 June 2025 | Chicago, IL & Online
The 2025 ASCO Annual Meeting took place in Chicago, IL, and online. This meeting attracted thousands of researchers and clinicians who shared the latest advances in the oncology field.
View all videos

Latest videos

View all videos
3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
4:15
The incidence of VTE following induction therapy in patients with newly diagnosed multiple myeloma
Muhamed Baljević • 14 Jun 2025
2:37
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
Shaji Kumar • 17 Jun 2025
1:10
CAR T-cell therapy for R/R secondary CNS lymphoma: real-world outcomes
Sairah Ahmed • 13 Jun 2025

Lymphoma

View all
1:10
CAR T-cell therapy for R/R secondary CNS lymphoma: real-world outcomes
Sairah Ahmed • 13 Jun 2025
4:28
Exploring the use of a novel deep learning-based MRI to better identify ICANS after CAR-T
Kathryn Tringale • 12 Jun 2025

Multiple myeloma

View all
3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
4:15
The incidence of VTE following induction therapy in patients with newly diagnosed multiple myeloma
Muhamed Baljević • 14 Jun 2025

Treatment

View all
3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
4:15
The incidence of VTE following induction therapy in patients with newly diagnosed multiple myeloma
Muhamed Baljević • 14 Jun 2025

Trial Updates

View all
3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
2:37
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
Shaji Kumar • 17 Jun 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals